Company profile: Leukocare
1.1 - Company Overview
Company description
- Provider of biopharmaceutical formulation development services operating at the interface of drug substance and drug product, combining bioinformatics, artificial intelligence and data science. Offerings include drug substance characterization, developability assessment, particle characterization, stability studies, and in silico analytics to optimize and accelerate development.
Products and services
- Developability Assessment: Leukocare evaluates drug candidates’ drug-like properties and development potential using in silico and in vitro methods to determine suitability for development, in silico-driven
- Formulation Development: Leukocare architects biopharmaceutical formulations for a range of biopharmaceuticals, employing data science and analytics to optimize compositions at the drug substance–drug product interface, analytics-powered
- Stability Studies: Leukocare conducts comprehensive stability testing from early development stages to shelf life prediction, generating data that supports regulatory filings for drug products, regulatory-supportive
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Leukocare
Nordic Bioscience
HQ: Denmark
Website
- Description: Provider of ECM-focused biomarker technologies and services for precision drug development, including Protein Fingerprint technology to quantify extracellular matrix fragments in blood, laboratory biomarker analysis for clinical trials, the PRO-C3 biomarker for type III collagen formation, and the GRIPonMASH platform for early MASH detection and management with AI-based decision support.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Nordic Bioscience company profile →
Arranta Bio
HQ: United States
Website
- Description: Provider of contract development and manufacturing services, including GMP RNA solutions (plasmid, RNA, lipid nanoparticle production), biologics development and cGMP manufacturing, viral vector and live virus manufacturing, GMP cell and virus banking, and microbiome services developing and manufacturing live biotherapeutic products.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Arranta Bio company profile →
Crown Bioscience
HQ: United States
Website
- Description: Provider of translational preclinical research solutions for oncology, cardiovascular, and metabolic disease drug discovery, including patient-derived xenograft (PDX) models, organoid and cell line models, in vitro screening and pharmacology characterization, in vivo development support, cancer model databases, and high-content imaging to analyze tumor growth and disease progression.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Crown Bioscience company profile →
Eucodis Bioscience
HQ: Austria
Website
- Description: Provider of high-performance enzyme solutions, offering enzyme engineering for industrial customers across the chemical, pharmaceutical, cosmetics, and food and feed industries.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Eucodis Bioscience company profile →
Cambrian Bio
HQ: United States
Website
- Description: Provider of therapeutics to lengthen healthspan via a Distributed Development Company model, advancing programs targeting biological drivers of aging, including ATX-304 (a pan-AMPK activator for cardiometabolic diseases, Phase 1B), Tornado Therapeutics (developing mTOR inhibitors with novel selectivity profiles), and Telovance (a protein complex to enhance ex-vivo cell therapy expansion).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cambrian Bio company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Leukocare
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Leukocare
2.2 - Growth funds investing in similar companies to Leukocare
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Leukocare
4.2 - Public trading comparable groups for Leukocare
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →